Fennec Pharmaceuticals Reports Record 2025 Sales, 50% Growth, and Eliminates All Debt

summarizeSummary

Fennec Pharmaceuticals announced strong full-year 2025 financial results, including record PEDMARK® sales growth and a significantly strengthened balance sheet with all debt repaid.

check_boxKey Events

• Record 2025 Product Sales

  Reported full-year 2025 net PEDMARK® product sales of $44.6 million, representing 50% year-over-year growth. Q4 2025 net product sales were $13.8 million, a 75% increase over Q4 2024.

• Strengthened Balance Sheet

  Completed $42 million in equity offerings and fully redeemed all outstanding debt, resulting in $36.7 million in cash and cash equivalents and $0 debt outstanding as of December 31, 2025.

• Clinical Program Expansion

  Presented new real-world data supporting PEDMARK® use in adults with head and neck cancer and initiated two new institution-led clinical studies to expand its application.

• Positive Japan Trial Results

  Announced positive topline results from an investigator-initiated Phase 2/3 clinical trial of PEDMARK® in Japan, demonstrating hearing protection without compromising efficacy, and is pursuing registration.

auto_awesomeAnalysis

Fennec Pharmaceuticals delivered a strong financial and operational update for full-year 2025. The company achieved record net product sales for PEDMARK®, demonstrating significant year-over-year growth and increasing adoption. Crucially, Fennec substantially strengthened its financial position by completing $42 million in equity offerings and fully redeeming all outstanding debt, resulting in a healthy cash balance and zero debt. This de-risks the balance sheet and provides a solid foundation for continued commercial expansion and clinical development. Positive clinical updates, including new real-world data and the initiation of additional studies, further support the long-term potential of PEDMARK®.